For immediate release |
23 June 2015 |
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified on 23 June 2015 that on 23 June 2015, Lynette Booley, spouse of Anthony Booley, an-Executive Director of the Company, sold 1,000,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 37.0 pence per share, and Anthony Booley sold 1,155,000 Ordinary Shares on the same date at the same price.
Following this transaction, Mr Booley's total beneficial interest in the Company is 2,055,723 Ordinary Shares, representing approximately 0.78% of the Company's issued share capital.
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive |
|
|
|
www.alliancepharma.co.uk |
|
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.